Making better influenza virus vaccines? - Wikidata - thesis-toulmin - TriplyDB

Making better influenza virus vaccines?

Making better influenza virus vaccines?

http://www.wikidata.org/entity/Q22305647

about

Confronting potential influenza A (H5N1) pandemic with better vaccines Sublingual immunization with a live attenuated influenza a virus lacking the nonstructural protein 1 induces broad protective immunity in mice Pandemics, avian influenza A (H5N1), and a strategy for pharmacists.The osmotic stress response of split influenza vaccine particles in an acidic environment.Avian influenza: a pandemic waiting in the wings?Scientific barriers to developing vaccines against avian influenza viruses.The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus.Influenza vaccines: a moving interdisciplinary field.Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.Toward a broadly protective influenza vaccine Efficient generation of influenza virus with a mouse RNA polymerase I-driven all-in-one plasmid Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.Role of CD8(+) T-cell immunity in influenza infection: potential use in future vaccine development.Establishment and characterization of a Madin-Darby canine kidney reporter cell line for influenza A virus assays Biopolymer encapsulated live influenza virus as a universal CD8+ T cell vaccine against influenza virus.Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccine A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains.TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice.N-linked glycosylation in the hemagglutinin of influenza A viruses.Vaccination against influenza: role and limitations in pandemic intervention plans.Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice Production of avian influenza virus vaccine using primary cell cultures generated from host organs.Novel inhibitor of influenza non-structural protein 1 blocks multi-cycle replication in an RNase L-dependent manner.A step closer to meeting the threat of avian influenza.Improved and simplified recombineering approach for influenza virus reverse genetics.Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.Cytotoxic T cells are the predominant players providing cross-protective immunity induced by {gamma}-irradiated influenza A viruses.The dichotomy of pathogens and allergens in vaccination approaches A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) population.Fast vaccine design and development based on correlates of protection (COPs).Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity.Robust immunity and heterologous protection against influenza in mice elicited by a novel recombinant NP-M2e fusion protein expressed in E. coli A mechanistic study on the destabilization of whole inactivated influenza virus vaccine in gastric environment.Animal models for influenza viruses: implications for universal vaccine development Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach.Modifications of cysteine residues in the transmembrane and cytoplasmic domains of a recombinant hemagglutinin protein prevent cross-linked multimer formation and potency loss Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies.The DBA.2 mouse is susceptible to disease following infection with a broad, but limited, range of influenza A and B viruses.Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.

P2860

Q24601560-8B80F919-AE6F-4790-A1BC-3A3D04BE726D Q28727930-E684FFB4-5BA9-46FC-9EB0-E1EFDE4848A1 Q30353151-BB6330BE-42F0-4A1C-ADF8-99A7804A6784 Q30354213-00ABBE16-A34B-47D9-AEF3-001EF2115467 Q30357794-E59F6D21-DB0D-4EF0-86AC-67FACD4DCB04 Q30360468-97A20E9B-31D5-4A92-864C-4CD8FD5EEA3B Q30367176-380D2643-243D-4CB1-9DB5-CF80D51F8CD2 Q30367695-A6FFEB57-CAA8-4D63-BB3C-42C383934267 Q30372024-61D7B09A-D53F-4E99-A554-7DCFAE884469 Q30372130-A5592953-6E0C-4FD3-891E-29D11E6BADC7 Q30375917-45153A93-E6A6-4CA4-A267-7CCC62E4E409 Q30375982-1341BE7F-062F-4D4C-978B-5C5C3D8BC9C2 Q30382567-A518626A-94A0-4C40-806F-2F4A5057779D Q30389274-E5D1ABEA-E926-484A-8A10-ECFD423F11E0 Q30389713-B7B012E6-8757-45E2-AF88-A49007545878 Q30395580-0534002A-1020-49E8-BB27-14B25FD4B923 Q30400146-140E65B7-7244-4374-8129-7EDD3690E6DC Q30402334-94675120-5B04-4B32-99F0-D7041B4D706F Q30419734-F42C67C5-B970-4440-AE24-23160FE1081E Q30420126-78AD0966-841D-49EA-B835-1378650EBA55 Q30421562-DD2F8CDB-1D1A-43EA-898F-CEF8D7EC3387 Q30425194-D0DA5756-73E9-4D5E-95B0-08E1B46D2FE6 Q30428538-151E356E-FC44-4C66-ABD3-7294108CD43F Q30429134-93754781-1891-4E8E-A545-0B86A5F766C3 Q33257256-58DF89FD-15E0-4A70-ADF0-D80224FF5D84 Q33588096-DD901989-E094-4288-8B81-D65BAF0E0772 Q33676505-9F2FBC33-04F2-499A-BCA2-A7B723C7096E Q33826722-53509205-4BD4-4FE0-A3FA-FF939C4E8D3D Q33909251-83A14230-C523-4F0E-ACD0-F5F5811121D9 Q34198807-38A96B4D-AA4D-4E92-91EA-4AB82A380552 Q34291098-305E070A-6BDB-4BA3-A555-0AA81BB0EF91 Q34511080-A13FFF8D-BF90-4168-B392-BCB56D2D270E Q34533990-1AD130AD-A0FE-4074-9D14-37527DA527D0 Q34776559-003F7872-3909-4D7B-827D-B11C622E43A4 Q34809686-80F290FD-E6D2-464F-BC9D-F35918B31592 Q34820655-1122D3CA-D2F8-4C1D-B851-9775E331FADA Q35061360-88AF5CB1-6EA3-4AC1-A196-11F8045DE849 Q35110992-D6DE80E3-EF9E-419B-A9BB-BECF165F4AE4 Q35531496-0590AE35-C3B5-4EB8-9B3C-871ECE788186 Q35656657-A77EBEB1-C64C-43A8-A8A9-3B2B57C13CD2

P2860

Making better influenza virus vaccines?

http://www.wikidata.org/entity/Q22305647

description

2006 nî lūn-bûn

@nan

2006 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Making better influenza virus vaccines?

@ast

Making better influenza virus vaccines?

@en

Making better influenza virus vaccines?

@en-gb

Making better influenza virus vaccines?

@nl

type

label

Making better influenza virus vaccines?

@ast

Making better influenza virus vaccines?

@en

Making better influenza virus vaccines?

@en-gb

Making better influenza virus vaccines?

@nl

prefLabel

Making better influenza virus vaccines?

@ast

Making better influenza virus vaccines?

@en

Making better influenza virus vaccines?

@en-gb

Making better influenza virus vaccines?

@nl

P1433

Q22305647-49B79998-E502-4838-80D6-195514F04373

P1476

Q22305647-2029A0AD-82F8-4D71-B9ED-5D6441CD2EFE

P2860

Q22305647-0B0AA045-0D0E-4501-8322-BFB1F669B20E

Q22305647-1F35EEB6-3876-48B4-9DFB-E1BE6F119493

Q22305647-23B589DA-55FD-47DA-9D5C-DA9C1989F1C5

Q22305647-2D544DD2-6B2D-47ED-8894-0301F5105CCC

Q22305647-3E34691C-C226-4463-9C28-A96B87EA5978

Q22305647-4011F95B-C9E9-4C9B-A933-DC4C2C03F7DE

Q22305647-45F24824-AD31-438A-AF0A-F05FE654608C

Q22305647-49C4B9E4-63DE-4A42-97C2-F3985E057F5B

Q22305647-4FBC27CD-03A5-4B55-A95E-D6D144794DD9

Q22305647-5D58624A-CF16-4380-B4DD-28FBCC80AEAC

P304

Q22305647-22B3F1B3-AFFB-47CE-93A9-A1BFFB7F4A04

P31

Q22305647-2DC5C743-1EE2-4293-B37E-17FEC1DBE893

Q22305647-93BCEBB5-E526-4857-AD61-707570DB4C42

P356

Q22305647-10A42912-3347-46DC-A7F8-A00BF68658F0

P407

Q22305647-91FBC06D-E00F-4197-BD4D-76D0D60B8BB6

P433

Q22305647-5AF047D5-77CD-4C7E-B8B4-05C8D906744F

P478

Q22305647-DE1FA38F-2EC4-43A2-9FD5-AD00FA771951

P50

Q22305647-D5CF10C6-7D30-4FF3-8F31-EAD546BE9268

P577

Q22305647-A012390F-ACBA-4E1C-A767-6AD1AB320139

Q22305647-AEE5CB43-B71C-4B60-9A52-29388CE874A0

P5875

Q22305647-1D96A49C-4DF6-4AAF-9181-7A736B87595E

P698

Q22305647-A0DCA956-FA09-432F-9210-1197EFA21FFD

P921

Q22305647-179462AD-7A84-4F2A-8757-930463C14E5E

Q22305647-82ADFA02-F8C2-4FC3-B575-3A9FFE413AF0

P932

Q22305647-F3F42BAF-2749-42EC-BDCB-C03872898E7F

P356

P1433

Emerging Infectious Diseases

P1476

Making better influenza virus vaccines?

@en

P2860

The virosome concept for influenza vaccines

Influenza: old and new threats

Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems

Generation of influenza A viruses entirely from cloned cDNAs

A DNA transfection system for generation of influenza A virus from eight plasmids

Are we ready for pandemic influenza?

Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection.

Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs.

P304

61-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3201/EID1201.051043

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7282079

http://www.w3.org/2001/XMLSchema#string

P698

16494719

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

3291403

http://www.w3.org/2001/XMLSchema#string